US Patent

US8377880 — Therapeutic agents for reducing parathyroid hormone levels

Composition of Matter · Assigned to Kai Pharmaceuticals Inc · Expires 2030-07-29 · 4y remaining

Vulnerability score 10/100 Ironclad — strong claim type, well-established, deep family

What this patent protects

This patent protects compounds that lower parathyroid hormone levels, which can be used to treat hyperparathyroidism, bone disease, and hypercalcemic disorders.

USPTO Abstract

Compounds having activity for lowering parathyroid hormone levels are described. In one embodiment, the compounds are comprised of a contiguous sequence of subunits, X 1 —X 2 —X 3 —X 4 —X 5 —X 6 —X 7 , wherein the X 1 subunit comprises a thiol-containing moiety and the distribution of charge on the X 2 —X 7 subunits provides the desired activity. Methods of using the compounds for treating hyperparathyroidism, bone disease and/or hypercalcemic disorders are also described, and in particular, methods for lowering plasma PTH and serum calcium are provided. The compounds can be used to treat subjects having, for example: primary, secondary or tertiary hyperparathyroidism; hypercalcemia of malignancy; metastatic bone disease; or osteoporosis.

Drugs covered by this patent

Patent Metadata

Patent number
US8377880
Jurisdiction
US
Classification
Composition of Matter
Expires
2030-07-29
Drug substance claim
Yes
Drug product claim
Yes
Assignee
Kai Pharmaceuticals Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.